Genetic and molecular subtype heterogeneity in newly diagnosed early- and advanced-stage endometrial cancer
CONCLUSIONS: Our findings demonstrate the molecular heterogeneity within and across histologic types of EC and the increased genomic complexity of advanced-stage ECs. Molecular subtypes are present across EC histologic types and may help stratify EC patients for prognostic and therapeutic purposes.PMID:33622519 | DOI:10.1016/j.ygyno.2021.02.015 (Source: Gynecologic Oncology)
Source: Gynecologic Oncology - February 24, 2021 Category: Cancer & Oncology Authors: Arnaud Da Cruz Paula Deborah F DeLair Lorenzo Ferrando Daniel J Fix Robert A Soslow Kay J Park Sarah Chiang Jorge S Reis-Filho Ahmet Zehir Mark T A Donoghue Michelle Wu David N Brown Rajmohan Murali Claire F Friedman Dmitriy Zamarin Vicky Makker Jennifer Source Type: research

The role of the genetic testing industry in patient education of hereditary cancer: An observational study assessing the quality of patient education videos
CONCLUSIONS: There is significant variation in the content of pre-test patient education videos between GT companies. None of the videos met the SOC for pre-test GC, and none addressed disadvantages of GT, possibly due to a conflict of interest. With improvement in content, accessibility, and use of interactive platforms, these videos may serve as an adjunct to in-person pre-test GC.PMID:33618842 | DOI:10.1016/j.ygyno.2021.02.013 (Source: Gynecologic Oncology)
Source: Gynecologic Oncology - February 23, 2021 Category: Cancer & Oncology Authors: D C Greenberg D Kamara Z Tatsugawa M Mendoza E Pineda C H Holschneider M Zakhour Source Type: research

Accuracy of computerized tomography in the preoperative evaluation of metastases in primary vulvar cancer - A population-based study
Gynecol Oncol. 2021 Feb 20:S0090-8258(21)00141-4. doi: 10.1016/j.ygyno.2021.02.005. Online ahead of print.ABSTRACTOBJECTIVE: To investigate the impact of a preoperative CT on surgical decision making in primary vulvar squamous cell carcinoma (VSCC) and the accuracy of detecting inguinal lymph node metastases (LNM). Secondly to assess prevalence and consequences of incidental findings and comorbidity using a CT.METHODS: This population-based study comprised of surgically treated patients with primary VSCC, at a regional tertiary center, using the Swedish Quality Registry for Gynecological Cancer for identification, and medi...
Source: Gynecologic Oncology - February 23, 2021 Category: Cancer & Oncology Authors: Katja Stenstr öm Bohlin Anna-Karin Bruno Cecilia von Knorring Camilla Rahm Henrik Leonhardt Source Type: research

Cervical cancer survivors and health care use: A Danish population-based register study
CONCLUSIONS: A CC diagnosis was followed by an increase in use of GPs, hospitals, and analgesic/psychotropic prescription drugs, while use of psychologist/psychiatrist was largely unaffected. This pattern may indicate that pain/mental health concerns after CC either persisted or were alleviated by other means only.PMID:33618844 | DOI:10.1016/j.ygyno.2021.02.003 (Source: Gynecologic Oncology)
Source: Gynecologic Oncology - February 23, 2021 Category: Cancer & Oncology Authors: Malene Skorstengaard Maria Eiholm Frederiksen Miguel V ázquez-Prada Baillet Anna-Belle Beau Pernille Tine Jensen Carsten Rygaard Jesper Hallas Elsebeth Lynge Source Type: research

The role of the genetic testing industry in patient education of hereditary cancer: An observational study assessing the quality of patient education videos
CONCLUSIONS: There is significant variation in the content of pre-test patient education videos between GT companies. None of the videos met the SOC for pre-test GC, and none addressed disadvantages of GT, possibly due to a conflict of interest. With improvement in content, accessibility, and use of interactive platforms, these videos may serve as an adjunct to in-person pre-test GC.PMID:33618842 | DOI:10.1016/j.ygyno.2021.02.013 (Source: Gynecologic Oncology)
Source: Gynecologic Oncology - February 23, 2021 Category: Cancer & Oncology Authors: D C Greenberg D Kamara Z Tatsugawa M Mendoza E Pineda C H Holschneider M Zakhour Source Type: research

Accuracy of computerized tomography in the preoperative evaluation of metastases in primary vulvar cancer - A population-based study
Gynecol Oncol. 2021 Feb 20:S0090-8258(21)00141-4. doi: 10.1016/j.ygyno.2021.02.005. Online ahead of print.ABSTRACTOBJECTIVE: To investigate the impact of a preoperative CT on surgical decision making in primary vulvar squamous cell carcinoma (VSCC) and the accuracy of detecting inguinal lymph node metastases (LNM). Secondly to assess prevalence and consequences of incidental findings and comorbidity using a CT.METHODS: This population-based study comprised of surgically treated patients with primary VSCC, at a regional tertiary center, using the Swedish Quality Registry for Gynecological Cancer for identification, and medi...
Source: Gynecologic Oncology - February 23, 2021 Category: Cancer & Oncology Authors: Katja Stenstr öm Bohlin Anna-Karin Bruno Cecilia von Knorring Camilla Rahm Henrik Leonhardt Source Type: research

Cervical cancer survivors and health care use: A Danish population-based register study
CONCLUSIONS: A CC diagnosis was followed by an increase in use of GPs, hospitals, and analgesic/psychotropic prescription drugs, while use of psychologist/psychiatrist was largely unaffected. This pattern may indicate that pain/mental health concerns after CC either persisted or were alleviated by other means only.PMID:33618844 | DOI:10.1016/j.ygyno.2021.02.003 (Source: Gynecologic Oncology)
Source: Gynecologic Oncology - February 23, 2021 Category: Cancer & Oncology Authors: Malene Skorstengaard Maria Eiholm Frederiksen Miguel V ázquez-Prada Baillet Anna-Belle Beau Pernille Tine Jensen Carsten Rygaard Jesper Hallas Elsebeth Lynge Source Type: research

Implications of the obesity epidemic for endometrial cancer risk, mortality, and survivorship
Gynecol Oncol. 2021 Mar;160(3):643-645. doi: 10.1016/j.ygyno.2021.02.007.NO ABSTRACTPMID:33612169 | DOI:10.1016/j.ygyno.2021.02.007 (Source: Gynecologic Oncology)
Source: Gynecologic Oncology - February 22, 2021 Category: Cancer & Oncology Authors: Ashley S Felix Mark E Sherman Source Type: research

Incorporating patient centered benefits as endpoints in randomized trials of maintenance therapies in advanced ovarian cancer: A position paper from the GCIG symptom benefit committee
CONCLUSIONS: Close attention to incorporating HRQL and PROM's is critical to interpret the results of ovarian cancer clinical trials of maintenance therapies. There should be a consistent approach to assessing and reporting patient centered benefits across all GCIG trials to enable cross trial comparisons which can be used to inform practice.PMID:33612336 | DOI:10.1016/j.ygyno.2021.02.018 (Source: Gynecologic Oncology)
Source: Gynecologic Oncology - February 22, 2021 Category: Cancer & Oncology Authors: Jean-Emmanuel Kurtz Val Gebski Vladyslav Sukhin Mark Carey Iwa Kong Rosalind M Glasspool Jonathan S Berek Mariana de Paiva Batista Marcia Hall Jae-Weon Kim Effi Yeoshoua Noriko Fujiwara Byung-Ho Nam Sandra Polleis Jung-Yun Lee Aleksandra Strojna Laura Far Source Type: research

Post hoc analyses of GOG 9923: Does BRCA status affect toxicities?: An NRG oncology study
CONCLUSIONS: Germline BRCA mutations positively affect chemosensitivity in EOC, but whether differences in toxicities among BRCA-associated and BRCA wild type tumors existed was previously not reported. In this population with newly diagnosed ovarian cancer no differences in reported toxicity between the two groups was observed.PMID:33610319 | DOI:10.1016/j.ygyno.2021.01.037 (Source: Gynecologic Oncology)
Source: Gynecologic Oncology - February 21, 2021 Category: Cancer & Oncology Authors: Jessica Gillen Austin Miller Katherine M Bell-McGuinn Russell J Schilder Joan L Walker Cara A Mathews Linda R Duska Saketh R Guntupalli Roisin O'Cearbhaill John Hays Andrea R Hagemann Heidi J Gray Sarah W Gordon Deborah K Armstrong Alice Chen Paula M Frac Source Type: research

Frailty Index for prediction of surgical outcome in ovarian cancer: Results of a prospective study
Gynecol Oncol. 2021 Feb 16:S0090-8258(21)00149-9. doi: 10.1016/j.ygyno.2021.02.012. Online ahead of print.ABSTRACTBACKGROUND: Complete macroscopic tumor resection is the strongest prognostic factor for patients with ovarian cancer, which requires complex surgery for achievement. Based on the mostly advanced tumor stage and high symptom burden many patients are classified as frail which may limit optimal surgical outcome. Aim of this study is to evaluate the predictive ability of Frailty Index for surgical outcomes in patients with ovarian cancer.METHODS: This prospective study enrolled patients with ovarian cancer undergoi...
Source: Gynecologic Oncology - February 20, 2021 Category: Cancer & Oncology Authors: Melisa Guelhan Inci Louise Anders Hannah Woopen Rolf Richter Duygu Guzel Robert Armbrust Jalid Sehouli Source Type: research

Phase 2 study of anastrozole in patients with estrogen receptor/progesterone receptor positive recurrent low-grade endometrial stromal sarcomas: The PARAGON trial (ANZGOG 0903)
CONCLUSION: The 26.7% objective response rate with anastrozole is lower than reported in retrospective series, but the CBR was high and durable. The results underscore the importance of prospective trials in rare cancers.PMID:33608144 | DOI:10.1016/j.ygyno.2021.02.016 (Source: Gynecologic Oncology)
Source: Gynecologic Oncology - February 20, 2021 Category: Cancer & Oncology Authors: M Friedlander C Benson R L O'Connell N Reed A Clamp R Lord D Millan S Nottley F Amant C Steer A Anand L Mileshkin P Beale S Banerjee N Bradshaw C Kelly K Carty L Divers L Alexander R Edmondson Source Type: research

A Danish nationwide study of risk factors associated with Type I and Type II endometrial cancer
CONCLUSIONS: Risk factors for Type I and II tumors were overlapping suggesting that Type II tumors may be less estrogen-independent than previously anticipated. High-grade Type I tumors seemed to resemble Type II tumors more than low-grade Type I tumors.PMID:33608145 | DOI:10.1016/j.ygyno.2021.02.010 (Source: Gynecologic Oncology)
Source: Gynecologic Oncology - February 20, 2021 Category: Cancer & Oncology Authors: M T Faber C D Sperling A K K Bennetsen G L Aalborg S K Kjaer Source Type: research

Socioeconomic inequality and omission of adjuvant radiation therapy in high-risk, early-stage endometrial cancer
We examined whether demographic and socioeconomic factors influenced receipt of adjuvant radiation therapy (RT) in patients with high-risk, early-stage endometrial cancer.METHODS: A retrospective study cohort was selected from 349,404 endometrial carcinoma patients from the National Cancer Database in whom adjuvant RT would be recommended per national guidelines. The study included surgically treated patients with endometrioid endometrial cancer with one of the following criteria: 1) FIGO 2009 stage IB, grade 1/2 disease, age ≥ 60 years; 2) stage IB, grade 3 disease; or 3) stage II disease. Logistic regression analysis ...
Source: Gynecologic Oncology - February 18, 2021 Category: Cancer & Oncology Authors: Leo Y Luo Emeline M Aviki Anna Lee Marisa A Kollmeier Nadeem R Abu-Rustum C Jillian Tsai Kaled M Alektiar Source Type: research

Frailty Index for prediction of surgical outcome in ovarian cancer: Results of a prospective study.
Abstract BACKGROUND: Complete macroscopic tumor resection is the strongest prognostic factor for patients with ovarian cancer, which requires complex surgery for achievement. Based on the mostly advanced tumor stage and high symptom burden many patients are classified as frail which may limit optimal surgical outcome. Aim of this study is to evaluate the predictive ability of Frailty Index for surgical outcomes in patients with ovarian cancer. METHODS: This prospective study enrolled patients with ovarian cancer undergoing cytoreductive surgery. We classified frailty proposed by Mitnitski et al. regarding the...
Source: Gynecologic Oncology - February 16, 2021 Category: Cancer & Oncology Authors: Inci MG, Anders L, Woopen H, Richter R, Guzel D, Armbrust R, Sehouli J Tags: Gynecol Oncol Source Type: research

Phase 2 study of anastrozole in patients with estrogen receptor/progesterone receptor positive recurrent low-grade endometrial stromal sarcomas: The PARAGON trial (ANZGOG 0903).
CONCLUSION: The 26.7% objective response rate with anastrozole is lower than reported in retrospective series, but the CBR was high and durable. The results underscore the importance of prospective trials in rare cancers. PMID: 33608144 [PubMed - as supplied by publisher] (Source: Gynecologic Oncology)
Source: Gynecologic Oncology - February 16, 2021 Category: Cancer & Oncology Authors: Friedlander M, Benson C, O'Connell RL, Reed N, Clamp A, Lord R, Millan D, Nottley S, Amant F, Steer C, Anand A, Mileshkin L, Beale P, Banerjee S, Bradshaw N, Kelly C, Carty K, Divers L, Alexander L, Edmondson R Tags: Gynecol Oncol Source Type: research

A Danish nationwide study of risk factors associated with Type I and Type II endometrial cancer.
CONCLUSIONS: Risk factors for Type I and II tumors were overlapping suggesting that Type II tumors may be less estrogen-independent than previously anticipated. High-grade Type I tumors seemed to resemble Type II tumors more than low-grade Type I tumors. PMID: 33608145 [PubMed - as supplied by publisher] (Source: Gynecologic Oncology)
Source: Gynecologic Oncology - February 16, 2021 Category: Cancer & Oncology Authors: Faber MT, Sperling CD, Bennetsen AKK, Aalborg GL, Kjaer SK Tags: Gynecol Oncol Source Type: research

Socioeconomic inequality and omission of adjuvant radiation therapy in high-risk, early-stage endometrial cancer.
We examined whether demographic and socioeconomic factors influenced receipt of adjuvant radiation therapy (RT) in patients with high-risk, early-stage endometrial cancer. METHODS: A retrospective study cohort was selected from 349,404 endometrial carcinoma patients from the National Cancer Database in whom adjuvant RT would be recommended per national guidelines. The study included surgically treated patients with endometrioid endometrial cancer with one of the following criteria: 1) FIGO 2009 stage IB, grade 1/2 disease, age ≥ 60 years; 2) stage IB, grade 3 disease; or 3) stage II disease. Logistic...
Source: Gynecologic Oncology - February 14, 2021 Category: Cancer & Oncology Authors: Luo LY, Aviki EM, Lee A, Kollmeier MA, Abu-Rustum NR, Tsai CJ, Alektiar KM Tags: Gynecol Oncol Source Type: research

Prognostic impact of socioeconomic status on long-term survival of non-localized epithelial ovarian cancer ꟷ The Extreme study.
CONCLUSIONS: Non-localized ovarian cancer patients have a poor prognosis. Our data suggest that among Danish women with advanced ovarian cancer, higher personal income is associated with slightly higher probability of long-term survival, whereas education and marital status did not affect the probability of long-term survival. PMID: 33583579 [PubMed - as supplied by publisher] (Source: Gynecologic Oncology)
Source: Gynecologic Oncology - February 11, 2021 Category: Cancer & Oncology Authors: Baandrup L, Dehlendorff C, Hertzum-Larsen R, Hannibal CG, Kjaer SK Tags: Gynecol Oncol Source Type: research

What happens after menopause? (WHAM): A prospective controlled study of depression and anxiety up to 12  months after premenopausal risk-reducing bilateral salpingo-oophorectomy.
CONCLUSIONS: RRBSO leads to a rapid increase in clinically significant depressive and anxiety symptoms despite Hormone Therapy use. PMID: 33583580 [PubMed - as supplied by publisher] (Source: Gynecologic Oncology)
Source: Gynecologic Oncology - February 11, 2021 Category: Cancer & Oncology Authors: Hickey M, Moss KM, Brand A, Wrede CD, Domchek SM, Meiser B, Mishra GD, Joffe H Tags: Gynecol Oncol Source Type: research

Exosomal microRNAs and exosomal long non-coding RNAs in gynecologic cancers.
Abstract Gynecologic cancer is a group of any malignancies affecting reproductive tissues and organs of women, including ovaries, uterine, cervix, vagina, vulva, and endometrium. Several types of molecular mechanisms are associated with the progression of gynecologic cancers. Among it can be referred to the most widely studied non-coding RNAs (ncRNAs), specifically microRNAs (miRNAs) and long ncRNAs (lncRNAs). As yet, lncRNAs are known to serve key biological roles via various mechanisms, such as splicing regulation, chromatin rearrangement, translation regulation, cell-cycle control, genetic imprinting and mRNA d...
Source: Gynecologic Oncology - February 10, 2021 Category: Cancer & Oncology Authors: Hashemipour M, Boroumand H, Mollazadeh S, Tajiknia V, Nourollahzadeh Z, Rohani Borj M, Pourghadamyari H, Rahimian N, Hamblin MR, Mirzaei H Tags: Gynecol Oncol Source Type: research

Implementation of National Guidelines increased survival in advanced ovarian cancer - A population-based nationwide SweGCG study.
undqvist E, Stålberg K Abstract AIM: The first Swedish National Guidelines for Ovarian Cancer (NGOC) were published in 2012. We aimed to evaluate surgical outcomes and survival in patients with stage IIIC-IV disease, before and after the NGOC implementation. METHOD: Women with primary epithelial ovarian cancer, FIGO stage IIIC-IV, registered in the Swedish Quality Registry for Gynecologic Cancer 2008-2011 and 2013-2016 were included. Surgical outcomes were analyzed, including frequency of complete cytoreduction (R0). Relative survival (RS) and excess mortality rate ratios (EMRRs) were computed as measur...
Source: Gynecologic Oncology - February 10, 2021 Category: Cancer & Oncology Authors: Dahm-Kähler P, Holmberg E, Holtenman M, Rådestad AF, Borgfeldt C, Hjerpe E, Marcickiewicz J, Bjurberg M, Tholander B, Hellman K, Kjølhede P, Högberg T, Rosenberg P, Åvall-Lundqvist E, Stålberg K Tags: Gynecol Oncol Source Type: research

A cost-effectiveness analysis of three approaches for lymph node assessment in patients with low- and intermediate-risk endometrial cancer.
CONCLUSION: Sentinel lymph node mapping is the most cost-effective strategy to guide the need for adjuvant therapy in patients with low and intermediate risk endometrioid endometrial cancer. PMID: 33581847 [PubMed - as supplied by publisher] (Source: Gynecologic Oncology)
Source: Gynecologic Oncology - February 10, 2021 Category: Cancer & Oncology Authors: Burg LC, Vermeulen RJ, Bekkers RLM, Wijn SRW, Rovers MM, Govers TM, Zusterzeel PLM Tags: Gynecol Oncol Source Type: research

Clinical significance of homologous recombination deficiency score testing in endometrial Cancer.
Abstract BACKGROUND: Homologous recombination deficiency (HRD) score is related to chemotherapy response in some cancers, but its role in endometrial cancer in not known. We determined frequency and clinical significance of alterations in the HR pathway in endometrial cancer. METHODS: 253 endometrioid endometrial adenocarcinoma (EEA) samples from two independent cohorts (discovery and replication) were tested for HRD score using the Myriad HRD assay, microsatellite instability (MSI) and tumor mutation burden (TMB) using a next generation sequencing assay. HRD scores were also generated on endometrial cancer c...
Source: Gynecologic Oncology - February 6, 2021 Category: Cancer & Oncology Authors: Siedel JH, Ring KL, Hu W, Dood RL, Wang Y, Baggerly K, Darcy KM, Conrads TP, Gallagher S, Tshiaba P, Neff C, Timms KM, Mangala S, Westin SN, Broaddus R, Lopez-Berestein G, Lu KH, Coleman RL, Maxwell GL, Sood AK Tags: Gynecol Oncol Source Type: research

The impact of modern preoperative high-dose-rate brachytherapy in early-stage cervical cancer.
CONCLUSIONS: Preoperative image-guided adaptive brachytherapy followed by minimally invasive surgery allows high local control, reduces positive surgical margins and rates of lymph-vascular space invasion avoiding adjuvants treatments. Surgical approaches must be discussed with patients including preoperative brachytherapy as a down-staging treatment. PMID: 33563488 [PubMed - as supplied by publisher] (Source: Gynecologic Oncology)
Source: Gynecologic Oncology - February 6, 2021 Category: Cancer & Oncology Authors: Varela Cagetti L, Gonzague-Casabianca L, Zemmour C, Lambaudie E, Houvenaeghel G, Provansal M, Sabatier R, Sabiani L, Blache G, Jauffret C, Ferré M, Mailleux H, Paciencia M, Tallet A Tags: Gynecol Oncol Source Type: research

Prevention of venous thromboembolism in gynecological cancer patients undergoing major abdominopelvic surgery: A systematic review and network meta-analysis.
CONCLUSIONS: SCD plus LMWH might be safe and effective in VTE prevention following gynecological cancer surgery. However, the patient's bleeding risk should be considered to balance the risk and benefit of treatment. PMID: 33563489 [PubMed - as supplied by publisher] (Source: Gynecologic Oncology)
Source: Gynecologic Oncology - February 6, 2021 Category: Cancer & Oncology Authors: Insin P, Vitoopinyoparb K, Thadanipon K, Charakorn C, Attia J, McKay GJ, Thakkinstian A Tags: Gynecol Oncol Source Type: research

Corrigendum to "Pathological chemotherapy response score is prognostic in tubo-ovarian high-grade serous carcinoma: A systematic review and meta-analysis of individual patient data" Gynecol. Oncol. 154 (2019) 441-448.
Corrigendum to "Pathological chemotherapy response score is prognostic in tubo-ovarian high-grade serous carcinoma: A systematic review and meta-analysis of individual patient data" Gynecol. Oncol. 154 (2019) 441-448. Gynecol Oncol. 2021 Feb 05;: Authors: Cohen PA, Powell A, Böhm S, Gilks CB, Stewart CJR, Meniawy TM, Bulsara M, Avril S, Brockbank EC, Bosse T, de Azevedo Focchi GR, Ganesan R, Glasspool RM, Howitt BE, Kim HS, Lee JY, Le ND, Lockley M, Manchanda R, Mandalia T, McCluggage WG, McNeish I, Midha D, Srinivasan R, Tan YY, van der Griend R, Yunokawa M, Zannoni GF, HGSC CRS Collaborative N...
Source: Gynecologic Oncology - February 5, 2021 Category: Cancer & Oncology Authors: Cohen PA, Powell A, Böhm S, Gilks CB, Stewart CJR, Meniawy TM, Bulsara M, Avril S, Brockbank EC, Bosse T, de Azevedo Focchi GR, Ganesan R, Glasspool RM, Howitt BE, Kim HS, Lee JY, Le ND, Lockley M, Manchanda R, Mandalia T, McCluggage WG, McNeish I, Midha Tags: Gynecol Oncol Source Type: research

Re-thinking the prognostic significance of positive peritoneal cytology in endometrial cancer.
CONCLUSION: PC status was an independent prognostic factor of EC in all stages and tumor types. Early PC-positive cases, except for the low-risk group, may be recommended for upstaging and should be carefully managed compared with PC-negative cases. PMID: 33551195 [PubMed - as supplied by publisher] (Source: Gynecologic Oncology)
Source: Gynecologic Oncology - February 4, 2021 Category: Cancer & Oncology Authors: Takenaka M, Kamii M, Iida Y, Yanaihara N, Suzuki J, Takahashi K, Yanagida S, Saito M, Takano H, Yamada K, Okamoto A Tags: Gynecol Oncol Source Type: research

Dasatinib, paclitaxel, and carboplatin in women with advanced-stage or recurrent endometrial cancer: A pilot clinical and translational study.
CONCLUSIONS: Caveolin-1 expression, in combination with CRAF/BRAF heterodimerization, is associated with resistance to EphA2 targeting by dasatinib. The triplet combination showed interesting clinical activity in endometrial cancer with acceptable toxicity. Pretreatment with dasatinib may accentuate combination therapy toxicity. PMID: 33551196 [PubMed - as supplied by publisher] (Source: Gynecologic Oncology)
Source: Gynecologic Oncology - February 4, 2021 Category: Cancer & Oncology Authors: Coleman RL, Hu W, Soliman P, Nick A, Ramirez PT, Westin SN, Garcia ME, Zhu Z, Palancia J, Fellman BM, Yuan Y, Ram P, Bischoff F, Schmeler K, Bodurka D, Meyer LA, Sood AK Tags: Gynecol Oncol Source Type: research

Crowdsourcing to measure financial toxicity in gynecologic oncology.
Abstract OBJECTIVE: To utilize a novel crowdsourcing method to measure financial toxicity and its effects among a national cohort of gynecologic cancer patients. METHODS: Crowdsourcing methods were used to administer an online survey to women in the United States with gynecologic cancers. We used the Comprehensive Score for Financial Toxicity (COST) tool to measure financial toxicity and the EQ-5D-3L to measure quality of life (QOL). Based on prior work, we defined high financial toxicity as a COST score ≤ 23. We assessed correlation of COST scores with QOL. We used log-binomial regression to exa...
Source: Gynecologic Oncology - February 4, 2021 Category: Cancer & Oncology Authors: Esselen KM, Stack-Dunnbier H, Gompers A, Hacker MR Tags: Gynecol Oncol Source Type: research

Phase II trial evaluating efficacy of a Fitbit program for improving the health of endometrial cancer survivors.
CONCLUSIONS: Activity level was low and mildly improved on the Fitbit program with the telephone intervention, but effects did not persist by study completion. The program had the greatest impact on a select group of telephone intervention patients with high baseline walking frequency and low baseline step count. Others may require more intense intervention to promote more robust/persistent lifestyle changes. PMID: 33551199 [PubMed - as supplied by publisher] (Source: Gynecologic Oncology)
Source: Gynecologic Oncology - February 4, 2021 Category: Cancer & Oncology Authors: Rahimy E, Usoz M, von Eyben R, Fujimoto D, Watanabe D, Karam A, Jairam-Thodla A, Mills M, Dorigo O, Diver EJ, Teng N, English D, Kidd E Tags: Gynecol Oncol Source Type: research

Variations in incidence and mortality rates of endometrial cancer at the global, regional, and national levels, 1990-2019.
CONCLUSIONS: EC incidence has ubiquitously increased worldwide. EC mortality has decreased at the global level but increased in many countries. More efforts are required to alleviate the disease burden of EC. PMID: 33551200 [PubMed - as supplied by publisher] (Source: Gynecologic Oncology)
Source: Gynecologic Oncology - February 4, 2021 Category: Cancer & Oncology Authors: Gu B, Shang X, Yan M, Li X, Wang W, Wang Q, Zhang C Tags: Gynecol Oncol Source Type: research

Diagnostic value of indocyanine green fluorescence guided sentinel lymph node biopsy in vulvar cancer: A systematic review.
CONCLUSION: ICG for SLN mapping appears to be safe in women with vulvar cancer with a detection rate similar to the current techniques. A large prospective randomized controlled study with optimization of the technique is necessary to homogenize current practice and determine the true value of ICG in vulvar cancer. PROSPERO ID: CRD42020178261. PMID: 33551201 [PubMed - as supplied by publisher] (Source: Gynecologic Oncology)
Source: Gynecologic Oncology - February 4, 2021 Category: Cancer & Oncology Authors: Koual M, Benoit L, Nguyen-Xuan HT, Bentivegna E, Azaïs H, Bats AS Tags: Gynecol Oncol Source Type: research

Patterns of recurrence in women with advanced and recurrent epithelial ovarian cancer treated with cytoreductive surgery and hyperthermic intraperitoneal chemotherapy.
CONCLUSIONS: In women with advanced or recurrent EOC undergoing CRS+HIPEC, one-half of patients experience their first recurrence outside of the peritoneal cavity. Providers must be aware of the risk of EP failure in patients treated with CRS+HIPEC. PMID: 33551202 [PubMed - as supplied by publisher] (Source: Gynecologic Oncology)
Source: Gynecologic Oncology - February 4, 2021 Category: Cancer & Oncology Authors: Chambers LM, Yao M, Morton M, Gruner M, Chichura A, Horowitz M, Costales AB, Rose PG, Michener CM, Debernardo R Tags: Gynecol Oncol Source Type: research

Lymphadenectomy is associated with an increased risk of postoperative venous thromboembolism in early stage endometrial cancer.
Abstract OBJECTIVES: In patients undergoing surgery for early stage endometrial cancer, we sought to evaluate the effect of lymphadenectomy (LND), as well as surgical route, on the risk of postoperative venous thromboembolism (VTE). METHODS: The Surveillance, Epidemiology, and End Results cancer registries (2000-2013) linked to Medicare claims follow up from 1999 to 2014 was accessed to identify those with stage I-II endometrioid endometrial cancer who underwent hysterectomy. Performance of LND, 90-day incidence of postoperative VTE, open vs minimally invasive surgery (MIS), demographics, comorbidities, grade...
Source: Gynecologic Oncology - February 4, 2021 Category: Cancer & Oncology Authors: Latif N, Oh J, Brensinger C, Morgan M, Lin LL, Cory L, Ko EM Tags: Gynecol Oncol Source Type: research

The use of bevacizumab in the modern era of targeted therapy for ovarian cancer: A systematic review and meta-analysis.
CONCLUSIONS: Bevacizumab-containing regimens are associated with significant PFS benefit in advanced and recurrent epithelial ovarian cancer. While the difference in OS did not reach statistical significance in the first-line setting, bevacizumab was associated with improved survival in the recurrent setting. PMID: 33546867 [PubMed - as supplied by publisher] (Source: Gynecologic Oncology)
Source: Gynecologic Oncology - February 2, 2021 Category: Cancer & Oncology Authors: Liu S, Kasherman L, Fazelzad R, Wang L, Bouchard-Fortier G, Lheureux S, Krzyzanowska MK Tags: Gynecol Oncol Source Type: research

Impact of employment and insurance status on distress in gynecologic oncology patients.
Abstract OBJECTIVES: To study associations among employment, insurance status, and distress in gynecologic oncology patients; and to evaluate the impact of being unemployed or having no/Medicaid insurance on different distress problem areas. METHODS: In this single institution, cross-sectional analysis of gynecologic oncology patients, we screened for distress and problem areas using the National Comprehensive Cancer Network distress thermometer and problem list at outpatient appointments between 6/2017-9/2017. Primary outcome was self-reported high distress (score ≥ 5). The distress problem list...
Source: Gynecologic Oncology - February 2, 2021 Category: Cancer & Oncology Authors: Kuroki LM, Morris DH, Greenwade M, Landon M, Hagemann AR, Thaker PH, Massad LS, McCourt CK, Fuh KC, Powell MA, Mutch DG, Khabele D, Vanderlan JR Tags: Gynecol Oncol Source Type: research

Mutated p53 portends improvement in outcomes when bevacizumab is combined with chemotherapy in advanced/recurrent endometrial cancer: An NRG Oncology study.
CONCLUSIONS: This exploratory study suggests that combining chemotherapy with bevacizumab, but not temsirolimus, may enhance PFS and OS for patients whose tumors harbor mutant p53. These data set the stage for larger clinical studies evaluating the potential of TP53 mutational status as a biomarker to guide choice of treatment for endometrial cancer patients. Clintrials.gov: NCT00977574. PMID: 33541735 [PubMed - as supplied by publisher] (Source: Gynecologic Oncology)
Source: Gynecologic Oncology - February 1, 2021 Category: Cancer & Oncology Authors: Leslie KK, Filiaci VL, Mallen AR, Thiel KW, Devor EJ, Moxley K, Richardson D, Mutch D, Secord AA, Tewari KS, McDonald ME, Mathews C, Cosgrove C, Dewdney S, Casablanca Y, Jackson A, Rose PG, Zhou X, McHale M, Lankes H, Levine DA, Aghajanian C Tags: Gynecol Oncol Source Type: research

Disparities in pap smear screening follow up: A catalyst for collective action vs. collective despair.
PMID: 33500117 [PubMed - in process] (Source: Gynecologic Oncology)
Source: Gynecologic Oncology - January 29, 2021 Category: Cancer & Oncology Authors: Brooks SE, Davis EC, Farley JH Tags: Gynecol Oncol Source Type: research

Optimal overall treatment time for adjuvant therapy for women with completely resected, node-positive vulvar cancer.
This study aims to identify the impact of OTT on overall survival (OS) for women with completely resected, node-positive squamous cell carcinomas of the vulva. MATERIALS AND METHODS: The National Cancer Data Base was queried for women with surgically resected, node-positive vulvar squamous cell carcinomas between 2004 and 2016 who were treated with adjuvant radiation therapy. Kaplan-Meier analysis with log-rank test and Cox proportional hazards tests were utilized for OS calculations. RESULTS: A total of 1500 women met inclusion criteria. The median OTT was 104 days. Shorter OTT was associated with age, faci...
Source: Gynecologic Oncology - January 23, 2021 Category: Cancer & Oncology Authors: Ashmore S, Crafton SM, Miller EM, Krivak TC, Glaser SM, Teterichko SR, Sukumvanich P, Viswanathan AN, Beriwal S, Horne ZD Tags: Gynecol Oncol Source Type: research

Unwittingly biased: A note to gynecologic cancer providers.
PMID: 33485640 [PubMed - as supplied by publisher] (Source: Gynecologic Oncology)
Source: Gynecologic Oncology - January 20, 2021 Category: Cancer & Oncology Authors: Chase DM, Salani R, Farley J, Torres T, Stone J Tags: Gynecol Oncol Source Type: research

Sentinel node mapping vs. sentinel node mapping plus back-up lymphadenectomy in high-risk endometrial cancer patients: Results from a multi-institutional study.
CONCLUSIONS: Although the small sample size, and the retrospective study design this study highlighted that type of nodal assessment did not impact survival outcomes in high-risk EC. Theoretically, back-up lymphadenectomy would be useful in improving the removal of positive nodes, but its therapeutic value remains controversial. Further prospective evidence is needed. PMID: 33485641 [PubMed - as supplied by publisher] (Source: Gynecologic Oncology)
Source: Gynecologic Oncology - January 20, 2021 Category: Cancer & Oncology Authors: Bogani G, Papadia A, Buda A, Casarin J, Di Donato V, Gasparri ML, Plotti F, Pinelli C, Paderno MC, Lopez S, Perrone AM, Barra F, Guerrisi R, Brusadelli C, Cromi A, Ferrari D, Chiapp V, Signorelli M, Maggiore ULR, Ditto A, Palaia I, Ferrero S, De Iaco P, A Tags: Gynecol Oncol Source Type: research

Understanding the clinical implication of mismatch repair deficiency in endometrioid endometrial cancer through a prospective study.
The objective of this study was to compare the oncologic outcomes and recurrence patterns between MMRd and MMR-intact (MMRi) endometrioid EC (EEC). METHODS: Between 2015 and 2018, we prospectively recruited 492 EEC cases from three cancer centers in Ontario, Canada. Tumors were reflexively assessed for MMR protein expression by immunohistochemistry (IHC). Clinicopathological, survival and recurrence patterns were compared between MMRd and MMRi cases. RESULTS: Of 492 EEC, 348 were MMRi (71%) and 144 were MMRd (29%) with median follow-up of 16.8 months (0-69.6). MMRd tumors tended to be grade 2 or 3 (56% vs. 29%, p 
Source: Gynecologic Oncology - January 18, 2021 Category: Cancer & Oncology Authors: Kim SR, Tone A, Kim RH, Cesari M, Clarke BA, Eiriksson L, Hart T, Aronson M, Holter S, Lytwyn A, Lajkosz K, Oldfield L, Gallinger S, Bernardini MQ, Oza AM, Djordjevic B, Lerner-Ellis J, Van de Laar E, Vicus D, Pugh T, Pollett A, Ferguson SE Tags: Gynecol Oncol Source Type: research

Impact of intra-operative factors upon peri-operative outcomes in women undergoing hyperthermic intraperitoneal chemotherapy for gynecologic cancer.
Abstract OBJECTIVES: To evaluate the incidence of intra-operative metabolic and electrolyte abnormalities and subsequent impact on peri-operative outcomes in women with gynecologic cancer undergoing cytoreductive surgery with hyperthermic intraperitoneal chemotherapy (CRS + HIPEC). METHODS: An IRB-approved single institution retrospective cohort study was performed in women with gynecologic cancer who underwent CRS + HIPEC. Patient demographics, intra-operative electrolyte and metabolic values and peri-operative outcomes were recorded. To assess the association of pH and lactate upon post-...
Source: Gynecologic Oncology - January 16, 2021 Category: Cancer & Oncology Authors: Chichura A, Chambers LM, Costales AB, Yao M, Gruner M, Morton M, Rose PG, Vargas R, Michener CM, Debernardo R Tags: Gynecol Oncol Source Type: research

Live births and maintenance with levonorgestrel IUD improve disease-free survival after fertility-sparing treatment of atypical hyperplasia and early endometrial cancer.
Abstract OBJECTIVE: Our objectives were to (1) compare different regimens of hormonal therapy (HT) in young women with atypical endometrial hyperplasia (AEH) and early endometrial cancer (EC), (2) assess reproductive and oncologic outcomes and (3) explore possible predictors of complete response (CR) and disease free survival (DFS). METHODS: Reproductive age women with AEH and Grade 1-2 endometrioid EC with no or minimal myometrial invasion on MRI treated with different regimens of HT were prospectively analyzed. Treatment protocols included levonorgestrel intrauterine device (LNG IUD), gonadotropin-releasing...
Source: Gynecologic Oncology - January 15, 2021 Category: Cancer & Oncology Authors: Novikova OV, Nosov VB, Panov VA, Novikova EG, Krasnopolskaya KV, Andreeva YY, Shevchuk AS Tags: Gynecol Oncol Source Type: research

Perceived social support in patients with endometrial or ovarian cancer: A secondary analysis from the ROGY care study.
This study assessed whether socio-demographic, personality, and clinical characteristics predict the level of perceived social support in patients with endometrial or ovarian cancer. METHODS: Patients with endometrial or ovarian cancer who participated in the ROGY Care study and completed the Multidimensional Scale of Perceived Social Support(MSPSS) 12 months after inclusion were eligible for this study (n=238). Logistic regression analysis was conducted to determine the predictive value of socio-demographic characteristics, personality and clinical characteristics after initial treatment on the perceived level o...
Source: Gynecologic Oncology - January 13, 2021 Category: Cancer & Oncology Authors: Scheepers ERM, de Rooij BH, Pijnenborg JMA, van Huis-Tanja LH, Ezendam NPM, Hamaker ME Tags: Gynecol Oncol Source Type: research

The relationship of human papillomavirus and cytology co-testing results with endometrial and ovarian cancer diagnoses.
Abstract BACKGROUND: To investigate whether routine cervical screening using human papillomavirus (HPV) and cytology co-testing effectively identifies women with endometrial (EC) or ovarian (OvC) cancer. METHODS: In 2003, Kaiser Permanente Northern California implemented triennial co-testing in women aged ≥30 years. Index screening results (n = 2,385,729) were linked to subsequent EC (n = 3434) and OvC (n = 1113) diagnoses from January 1, 2003 to December 31, 2017. EC were categorized as type 1 or 2, and, selectively, EC and OvC diagnoses were stratified on whether sympto...
Source: Gynecologic Oncology - January 13, 2021 Category: Cancer & Oncology Authors: Castle PE, Locke A, Tergas AI, Befano B, Poitras N, Shah NR, Schiffman M, Wentzensen N, Strickler HD, Clarke MA, Lorey T Tags: Gynecol Oncol Source Type: research

Endometrial cancer: A society of gynecologic oncology evidence-based review and recommendations, part II.
Abstract In 2014, the Society of Gynecologic Oncology's Clinical Practice Committee published a clinical update reviewing the treatment of women with endometrial cancer. At that time, there had been significant advances in the diagnosis, work-up, surgical management, and available treatment options allowing for more optimal care of affected women. This manuscript, Part II in a two-part series, includes specific recommendations on treatment of recurrent disease, post treatment surveillance and survivorship, considerations for younger women, and special situations. Part I covered histopathology and molecular patholo...
Source: Gynecologic Oncology - January 12, 2021 Category: Cancer & Oncology Authors: Hamilton CA, Pothuri B, Arend RC, Backes FJ, Gehrig PA, Soliman PT, Thompson JS, Urban RR, Burke WM Tags: Gynecol Oncol Source Type: research

Reducing unnecessary referrals for colposcopy in hrHPV-positive women within the Dutch cervical cancer screening programme: A modelling study.
CONCLUSIONS: To reduce the number of unnecessary referrals without increasing incidence and mortality by more than 2% in the Dutch cervical cancer screening programme, genotyping for HPV16 or HPV16/18 should be implemented with 12 months to repeat testing. PMID: 33451725 [PubMed - as supplied by publisher] (Source: Gynecologic Oncology)
Source: Gynecologic Oncology - January 12, 2021 Category: Cancer & Oncology Authors: Kaljouw S, Jansen EEL, Aitken CA, Harrijvan LM, Naber SK, de Kok IMCM Tags: Gynecol Oncol Source Type: research

Impact of past surgical history on perioperative outcomes in gynecologic surgery.
Abstract OBJECTIVE: We sought to determine if past surgical history is associated with perioperative outcomes for patients undergoing hysterectomy. METHODS: A retrospective cohort study was conducted at a single, tertiary, academic health system of women who underwent hysterectomy from May 2016 - May 2017. Past surgical history (PSH) involving any abdominal or pelvic surgery, baseline demographics and perioperative outcomes were collected. For purposes of analyses, PSH was defined using three algorithms: 1) any prior abdominopelvic surgery, 2) having had abdominopelvic surgeries likely to cause adhesive disea...
Source: Gynecologic Oncology - January 9, 2021 Category: Cancer & Oncology Authors: Ko EM, Aviles D, Koelper NC, Morgan MA, Cory L Tags: Gynecol Oncol Source Type: research